Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:1322:261-284.
doi: 10.1007/978-981-16-0267-2_10.

Peptide-Based Antiviral Drugs

N Arul Murugan  1 , K Muruga Poopathi Raja  2 , N T Saraswathi  3
Affiliations

Peptide-Based Antiviral Drugs

N Arul Murugan et al. Adv Exp Med Biol. 2021.

Abstract

Three types of chemical entities, namely, small organic molecules (organics), peptides, and biologics, are mainly used as drug candidates for the treatment of various diseases. Even though the peptide drugs are known since 1920 in association with the clinical use of insulin, only a limited number of peptides are currently used for therapeutics due to various disadvantages associated with them such as limited serum and blood stability, oral bioavailability, and permeability. Since, through chemical modifications and structure tuning, many of these limitations can be overcome, peptide-based drugs are gaining attention in pharmaceutical research. As of today, there are more than 60 peptide-based drugs approved by FDA, and over 150 peptides are in the advanced clinical studies. In this book chapter, the peptide-based lead compounds and drugs available for treating various viral diseases and their advantages and disadvantages when compared to small molecules drugs are discussed.

Keywords: Antiviral peptides; DNA recombinant technology; Half-life of peptides; Oral bioavailability; Permeability; Solid-phase peptide synthesis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Zumla A, Hui DS (2019) Emerging and reemerging infectious diseases global overview. Infect Dis Clin North Am 33:xiii–xix - PubMed - PMC - DOI
    1. Chan WC, White P (eds) (1999) Fmoc solid phase peptide synthesis: a practical approach. OUP Oxford, Oxford, UK
    1. Matsubara T, Onishi A, Saito T, Shimada A, Inoue H, Taki T, Nagata K, Okahata Y, Sato T (2010) Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy. J Med Chem 53:4441–4449 - PubMed - DOI - PMC
    1. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, Hay AJ, Gamblin SJ, Skehel JJ (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443:45–49 - PubMed - DOI
    1. Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, Wilson IA, García-Sastre A, Moran TM, Palese P (2010) Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 107:18979–18984 - PubMed - PMC - DOI

LinkOut - more resources